Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Porter

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Endocrine Connections|June 27, 2024
Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasiaDafydd Aled Rees, Deborah P Merke, Wiebke Arlt, et al.
Eclinicalmedicine|February 20, 2026
Corrigendum to "Effects of modified release hydrocortisone on restoration of early morning cortisol, quality of life, and fatigue in adrenal insufficiency (The CHAMPAIN study): a randomised, double-blind, double-dummy, cross-over study comparing Chronocort and Plenadren"[eClinical Medicine 91(2026); 103714]Alessandro Prete, Verena Theiler-Schwetz, Wiebke Arlt, et al.
Nanomaterials (Basel, Switzerland)|November 26, 2022
Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic PayloadRichard D Perrins, Lee-Anne McCarthy, Angela Robinson, et al.
British Journal of Haematology|January 20, 2007
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell diseaseElliott Vichinsky, Onyinye Onyekwere, John Porter, et al.
The Journal of Clinical Endocrinology and Metabolism|February 2, 2021
Modified-Release Hydrocortisone in Congenital Adrenal HyperplasiaDeborah P Merke, Ashwini Mallappa, Wiebke Arlt, et al.
Clinical Endocrinology|May 16, 2025
Switching Patients With Congenital Adrenal Hyperplasia to Modified-Release Hydrocortisone Capsules: Relative Bioavailability and Disease ControlRichard John M Ross, Wiebke Arlt, Aude Brac de la Perriere, et al.
Haematologica|December 3, 2009
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasMaria Domenica Cappellini, John Porter, Amal El-Beshlawy, et al.
Haematologica|October 20, 2018
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding studyMaria Domenica Cappellini, John Porter, Raffaella Origa, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 9, 2014
Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overloadDaniel M Sado, Viviana Maestrini, Stefan K Piechnik, et al.
Clinical Therapeutics|August 19, 2007
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemiaMaria Domenica Cappellini, Mohamed Bejaoui, Leyla Agaoglu, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Endocrine Connections|June 27, 2024
Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasiaDafydd Aled Rees, Deborah P Merke, Wiebke Arlt, et al.
Eclinicalmedicine|February 20, 2026
Corrigendum to "Effects of modified release hydrocortisone on restoration of early morning cortisol, quality of life, and fatigue in adrenal insufficiency (The CHAMPAIN study): a randomised, double-blind, double-dummy, cross-over study comparing Chronocort and Plenadren"[eClinical Medicine 91(2026); 103714]Alessandro Prete, Verena Theiler-Schwetz, Wiebke Arlt, et al.
Nanomaterials (Basel, Switzerland)|November 26, 2022
Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic PayloadRichard D Perrins, Lee-Anne McCarthy, Angela Robinson, et al.
British Journal of Haematology|January 20, 2007
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell diseaseElliott Vichinsky, Onyinye Onyekwere, John Porter, et al.
The Journal of Clinical Endocrinology and Metabolism|February 2, 2021
Modified-Release Hydrocortisone in Congenital Adrenal HyperplasiaDeborah P Merke, Ashwini Mallappa, Wiebke Arlt, et al.
Clinical Endocrinology|May 16, 2025
Switching Patients With Congenital Adrenal Hyperplasia to Modified-Release Hydrocortisone Capsules: Relative Bioavailability and Disease ControlRichard John M Ross, Wiebke Arlt, Aude Brac de la Perriere, et al.
Haematologica|December 3, 2009
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemiasMaria Domenica Cappellini, John Porter, Amal El-Beshlawy, et al.
Haematologica|October 20, 2018
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding studyMaria Domenica Cappellini, John Porter, Raffaella Origa, et al.
Journal of Magnetic Resonance Imaging : JMRI|August 9, 2014
Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overloadDaniel M Sado, Viviana Maestrini, Stefan K Piechnik, et al.
Clinical Therapeutics|August 19, 2007
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemiaMaria Domenica Cappellini, Mohamed Bejaoui, Leyla Agaoglu, et al.
Pageof 16